However, our results first identified AR as a risk factor for Xp11.2 tRCC and provided a novel molecular mechanism for the age‐dependent prognostic difference in tumour progression. This evidence concerns the gene AR and renal cell carcinoma associated with Xp11.2 translocations/TFE3 gene fusions.